Patent: 9,399,028
✉ Email this page to a colleague
Summary for Patent: 9,399,028
Title: | Treatment of drug resistant cancer |
Abstract: | The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods. |
Inventor(s): | Tavazoie; Sohail (New York, NY), Pencheva; Nora (New York, NY) |
Assignee: | The Rockefeller University (New York, NY) |
Application Number: | 14/486,466 |
Patent Claims: | see list of patent claims |
Details for Patent 9,399,028
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2032-08-13 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 10/04/2017 | ⤷ Try a Trial | 2032-08-13 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 08/27/2021 | ⤷ Try a Trial | 2032-08-13 |
Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | 05/18/2016 | ⤷ Try a Trial | 2032-08-13 |
Genentech, Inc. | TECENTRIQ | atezolizumab | Injection | 761034 | 03/08/2019 | ⤷ Try a Trial | 2032-08-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |